Evidence map›Paper›PMID 38889068›Full record

ArticleImmunotherapy2024

Pembrolizumab in an HIV-infected patient with glioblastoma.

Carlen A Yuen, Silin Bao, Melike Pekmezci, Fan Mo, Xiao-Tang Kong

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carlen A YuenDepartment of Neurology, Neuro-Oncology Division, University of California, Irvine, CA 92868, USA.ORCID 0000-0003-1950-8819
Silin BaoDepartment of Internal Medicine, Neurosciences Division, Community Regional Medical Center, Fresno, CA 93721, USA.
Melike PekmezciDepartment of Pathology, University of California, San Francisco, CA 94143, USA.
Fan MoDepartment of Internal Medicine, Neurosciences Division, Community Regional Medical Center, Fresno, CA 93721, USA.
Xiao-Tang KongDepartment of Neurology, Neuro-Oncology Division, University of California, Irvine, CA 92868, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persons living with human immunodeficiency virus (PLWH) carry increased risk for developing malignancies, including glioblastoma. Despite extensive investigations, both human immunodeficiency virus (HIV) and glioblastoma are incurable. Treatment for a patient with combined glioblastoma and HIV remains an unexplored need. Preliminary evidence suggests that immunotherapy may be effective for the simultaneous treatment of both HIV and cancer by reversing HIV latency and T cell exhaustion. We present a case of glioblastoma in a PLWH who was treated with pembrolizumab. Treatment was well tolerated and safe with a mixed response. Our patient did not develop any opportunistic infections, immune-related adverse events, or worsening of his immunodeficiency. To our knowledge, this is the first reported case of a PLWH and glioblastoma treated with immunotherapy.

Indexed as

Antibodies, Monoclonal, HumanizedBrain NeoplasmsGlioblastomaHIV InfectionsAntineoplastic Agents, ImmunologicalHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabcancer disparitiesglioblastomaHIVHIV latencyHIV reservoirhuman immunodeficiency virusimmunotherapyPD-1pembrolizumabprogrammed cell death 1 inhibitor

Identifiers

PMID38889068
PMCPMC11457652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.